PRAX
NASDAQ · Biotechnology
Praxis Precision Medicines I
$311.92
+17.27 (+5.86%)
Financial Highlights (FY 2026)
Revenue
13.03M
Net Income
-278,552,680
Gross Margin
—
Profit Margin
-2,137.5%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | 64.1% | 64.1% | 64.1% |
| Operating Margin | -2,340.3% | -34.3% | -33.8% | -33.3% |
| Profit Margin | -2,137.5% | -26.4% | -32.9% | -28.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 13.03M | 1.51B | 1.36B | 1.44B |
| Gross Profit | — | 966.44M | 869.60M | 923.58M |
| Operating Income | -304,955,771 | -516,700,221 | -458,009,123 | -479,499,456 |
| Net Income | -278,552,680 | -397,237,584 | -445,831,143 | -415,026,051 |
| Gross Margin | — | 64.1% | 64.1% | 64.1% |
| Operating Margin | -2,340.3% | -34.3% | -33.8% | -33.3% |
| Profit Margin | -2,137.5% | -26.4% | -32.9% | -28.8% |
| Rev Growth | — | +19.5% | +13.8% | +10.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 745.61M | 787.76M | 733.77M |
| Total Equity | — | 3.17B | 3.00B | 2.97B |
| D/E Ratio | — | 0.24 | 0.26 | 0.25 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -304,436,703 | -626,558,933 | -546,408,810 | -551,718,441 |
| Free Cash Flow | — | -309,826,002 | -348,261,984 | -373,057,198 |